CIDP (chronic inflammatory demyelinating polyneuropathy) trials in China

In China 13 Also abroad 43

13 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Where
Beijing, Fuzhou, Guangzhou, Guanzhou, Suzhou, Xi’an
Age
18 years and over
People
160 worldwide
Run by
argenx
See details and how to joinNCT07091630 · EU 2025-520805-10-00
Phase 2/3Taking people
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Where
Beijing, Changchun, Changsha, Chengdu, Chifeng, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an, Xi’an
Age
18 years and over
People
201 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05327114 · EU 2023-508425-28-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Where
Beijing, Changsha, Chengdu, Chifeng, Fujian, Guangdong, Guangzhou, Hefei, Jilin City, Shanghai, Sichuan, Suzhou, Taiyuan, Wuhan
Age
18 years to 75 years
People
256 worldwide
Run by
Dianthus Therapeutics
See details and how to joinNCT06858579
Phase 3Enrolling by invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
Where
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Wuhan, Xi'an
Age
18 years and over
People
300 worldwide
Run by
Sanofi
See details and how to joinNCT06859099 · EU 2024-517032-22-00
Phase 3Taking people
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Where
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Jiazhuang, Jinan, Nanchang, Shanghai, Wuhan, Xi'an
Age
18 years and over
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT06290141 · EU 2023-508338-33-00
Phase 1/2Taking people
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Where
Tianjin
Age
18 years to 60 years
People
27
Run by
Tianjin Medical University General Hospital
See details and how to joinNCT07022197
No phaseTaking people
Biomarkers in Autoimmune Disease of Nervous System
Where
Wuhan
Age
18 years and over
People
50,000
Run by
Tongji Hospital
See details and how to joinNCT06502015
Early phase 1Taking people
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Where
Wuhan
Age
18 years to 70 years
People
36
Run by
Tongji Hospital
See details and how to joinNCT07337785
Phase 1Taking people
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Where
Wuhan
Age
18 years to 75 years
People
6
Run by
Tongji Hospital
See details and how to joinNCT07526493
No phaseNot yet taking people in China
Tongji NADs Cohort
Where
Wuhan
Age
18 years to 80 years
People
1,550
Run by
Tongji Hospital
See details and how to joinNCT07333196
Early phase 1Taking people
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Where
Tianjin
Age
18 years and over
People
12
Run by
Tianjin Huanhu Hospital
See details and how to joinNCT06939166
Early phase 1Not yet taking people in China
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
Where
Beijing
Age
18 years to 75 years
People
25
Run by
Xuanwu Hospital, Beijing
See details and how to joinNCT06485232
Early phase 1Taking people
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Where
Wuhan
Age
18 years to 75 years
People
36
Run by
Tongji Hospital
See details and how to joinNCT04561557